The clinical lab giant is working with MD Anderson on an LDT for assessing cancer risk to drive uptake of recommended screenings and identify high-risk individuals for evaluation.

The protein biomarker-based test will be used to identify patients at high risk of cancer in order to prioritize them for conventional cancer screening methods.

The work will focus on addressing unmet needs in breast cancer, including the diagnosis and treatment of patients with rare cancer subtypes.

The three-year award from the National Institute for Health and Care Research will support finalization of the test as well as initial validation studies.

The test is the last of three multiplex bloodstream infection panels that the firm has designed for its Liaison Plex molecular testing instrument.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

The firm is maintaining its full-year guidance and expects to make the acquisition once Lex Diagnostics obtains 510(k) clearance of its system.

Multiple presentations at the meeting discussed the utility of circulating tumor DNA to guide treatment for colorectal cancer.